Table of Contents
- Introduction
- What is EYE103?
- Conditions Treated by EYE103
- How EYE103 Works
- Clinical Trials for EYE103
- How EYE103 is Administered
- Potential Benefits of EYE103
- Frequently Asked Questions
- Summary
- Glossary
Introduction
EYE103, also known as Restoret, is a new medication being developed to treat certain eye conditions. This article will provide you with important information about EYE103, including what it is, how it works, and the conditions it may help treat.[1][2]
What is EYE103?
EYE103 is a humanized antibody that has been specially formulated for injection into the eye. It is currently being studied as a potential treatment for certain eye diseases. An antibody is a type of protein that can target specific substances in the body.[1][2]
Conditions Treated by EYE103
EYE103 is being investigated for the treatment of two main eye conditions:
- Diabetic Macular Edema (DME): A condition that can occur in people with diabetes, where fluid builds up in the macula (the central part of the retina), causing vision problems.
- Neovascular Age-related Macular Degeneration (NVAMD): Also known as “wet” AMD, this is a condition where abnormal blood vessels grow under the retina, potentially leading to vision loss.
These conditions can significantly impact a person’s vision and quality of life.[1][2]
How EYE103 Works
While the exact mechanism of EYE103 is not fully described in the provided information, it is likely that as a humanized antibody, it targets specific proteins or factors involved in the development of DME and NVAMD. In some cases, it may be used in combination with other treatments, such as anti-VEGF medications, which help prevent the growth of abnormal blood vessels in the eye.[2]
Clinical Trials for EYE103
EYE103 is currently being studied in clinical trials to evaluate its safety and effectiveness. Two main studies are underway:
- EYE-RES-102: This is a large study comparing two doses of EYE103 with ranibizumab (a currently approved treatment) in patients with DME. The study will involve about 960 participants and last for two years.[1]
- EYE103-101: This is a two-part study looking at the safety and early effectiveness of EYE103 in patients with DME and NVAMD. It includes:
- A small initial study with about 12 participants to test different doses
- A larger study with about 80 participants to compare two selected doses
These trials will help researchers determine the best dose of EYE103 and how well it works compared to existing treatments.[2]
How EYE103 is Administered
EYE103 is given as an intravitreal injection. This means it is injected directly into the vitreous, the jelly-like substance inside the eye. In the clinical trials, patients receive injections at regular intervals, typically every 4 weeks during the first year. After that, the frequency may be adjusted based on each patient’s needs.[1][2]
Potential Benefits of EYE103
While the full results of the clinical trials are not yet available, researchers are studying EYE103 to see if it can provide benefits such as:
- Improved vision, measured by the ability to read more letters on an eye chart
- Reduced swelling in the retina
- Potentially longer-lasting effects compared to current treatments
- Possible benefits when used alone or in combination with other treatments
It’s important to note that these potential benefits are still being studied and are not guaranteed.[1][2]
Frequently Asked Questions
Is EYE103 approved for use yet?
No, EYE103 is still in clinical trials and is not yet approved for general use. It needs to complete these trials and be reviewed by regulatory agencies before it can be prescribed to patients outside of research studies.
How does EYE103 compare to current treatments?
One of the main goals of the ongoing clinical trials is to compare EYE103 to existing treatments like ranibizumab. Until these studies are completed, we won’t know for certain how EYE103 compares in terms of effectiveness and safety.
Are there any side effects of EYE103?
As with any medication, there may be potential side effects. The current clinical trials are designed to carefully monitor for any side effects. Specific information about side effects will become available as the studies progress and results are analyzed.
Summary
| Aspect | Details |
|---|---|
| Drug Name | EYE103 (also known as Restoret) |
| Type | Humanized antibody |
| Administration | Intravitreal injection |
| Conditions Treated | Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD) |
| Current Status | In clinical trials |
| Potential Benefits | Improved vision, reduced retinal swelling, possible longer-lasting effects |
Glossary
- Humanized antibody – A type of antibody created in a laboratory to be very similar to human antibodies, designed to target specific substances in the body.
- Intravitreal injection – A procedure where medication is injected directly into the vitreous (gel-like substance) of the eye.
- Diabetic Macular Edema (DME) – A complication of diabetes that causes swelling in the macula, the part of the retina responsible for detailed central vision.
- Neovascular Age-related Macular Degeneration (NVAMD) – An eye condition where abnormal blood vessels grow under the retina, potentially leading to vision loss.
- Anti-VEGF – A type of medication that blocks vascular endothelial growth factor, which is involved in the growth of abnormal blood vessels in the eye.
Trial sources
- [1]: https://clinicaltrials.gov/study/NCT06571045
- [2]: https://clinicaltrials.gov/study/NCT05919693
